

CERTIFICATE OF MAILING BY "EXPRESS MAIL"
UNDER 37 C.F.R. § 1.10

"Express Mail" mailing label number: EL880469755US
Date of Mailing: January 18, 2002

I hereby certify that this correspondence is being deposited with the United States Postal Service, utilizing the "Express Mail Post Office to Addressee" service addressed to **Assistant Commissioner for Patents, Washington, DC 20231** and mailed on the above Date of Mailing with the above "Express Mail" mailing label number.

Helena Beckmann (Signature)
Helena Beckmann
Signature Date: January 18, 2002

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

| | | |
|--|---|---------------------------|
| In re Application |) | <u>PATENT APPLICATION</u> |
| |) | |
| Inventor(s): |) | Gideon Bollag et al |
| |) | |
| SC/Serial No.: |) | Unknown |
| |) | |
| Filed: |) | Herewith |
| |) | |
| Title: Methods and Compositions for Treating |) | |
| Abnormal Cell Growth Related to |) | |
| Unwanted Guanine Nucleotide |) | |
| Exchange Factor Activity |) | |
| |) | |

PRELIMINARY AMENDMENT

Assistant Commissioner for Patents
Washington, DC 20231

Sir/Madam:

Please amend the above-identified Divisional Patent Application filed herewith, as follows:

In the Specification

Page 1, line 16 add a new paragraph:

PRIORITY DATA

-- This Application is a divisional of U.S. Patent Application No. 09/079,812, filed May 15, 1998, which claims priority from U.S. Provisional Application No. 60/049,879, filed June 17, 1997. --

In the Claims

Please delete claims in Group II (7-29 and 32-35), which have been allowed in U.S. Patent Application Serial No. 09,079,812, and will issue as U.S. Patent 6,340,575.

Remarks

Elections


Applicants elect to prosecute in the instant divisional application claims in Group I, (1-6, 30-31, 36-37 and 56-67), as set forth in the Office action mailed August 9, 1999 in the Parent Case.

Applicants will file additional divisional applications at a future time directed to claims in Groups III-IV.

The undersigned attorney hereby request that the Examiner transfer the Sequence Listing in the prior application (paper copy enclosed), filed and accepted on July 12, 2001 to the instant divisional application.

The Commissioner is hereby authorized to charge Deposit Account No. 15-0615 for any fees associated with this communication.

Date: January 18, 2002

By: 
Gregory Giotta, Ph.D.
Reg. No. 32, 028

ONYX Pharmaceuticals, Inc.
3031 Research Drive
Richmond, CA 94806
Telephone: (510) 262-8710
Facsimile: (510) 222-9700